Because of the risks biopsies can pose to patients, the FDA recommends only requiring them as part of trial participation if ...

British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

When Michael Adams was researching health insurance options in 2023, he had one very specific requirement: coverage for ...

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

The FDA has published a set of long-awaited recommendations to the industry to help ensure that pulse oximeters work correctly across all skin tones. | The FDA has published a set of long-awaited ...

As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. | Discover how Astellas builds innovation partnerships with ambitious organ ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...